Mizuho Raises Henry Schein (NASDAQ:HSIC) Price Target to $88.00

Henry Schein (NASDAQ:HSIC) had its price target hoisted by equities researchers at Mizuho from $81.00 to $88.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s price target indicates a potential upside of 8.02% from the company’s current price.

Other equities analysts have also issued reports about the company. Wells Fargo & Company increased their price target on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday. Morgan Stanley upped their price objective on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a report on Wednesday. Barrington Research set a $79.00 target price on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Evercore upped their price target on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Stock Performance

Shares of HSIC opened at $81.47 on Wednesday. The firm has a market capitalization of $9.34 billion, a PE ratio of 24.91, a P/E/G ratio of 2.43 and a beta of 0.88. The company has a quick ratio of 0.79, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $77.75 and a 200 day moving average price of $72.04. Henry Schein has a 52-week low of $60.56 and a 52-week high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts anticipate that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in Henry Schein by 47.3% in the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after acquiring an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after acquiring an additional 229 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Henry Schein in the 1st quarter valued at about $676,000. Asset Management One Co. Ltd. lifted its position in shares of Henry Schein by 9.8% in the second quarter. Asset Management One Co. Ltd. now owns 8,286 shares of the company’s stock worth $605,000 after purchasing an additional 739 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Henry Schein by 24.8% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,272 shares of the company’s stock worth $458,000 after purchasing an additional 1,247 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.